Developer docs
API playgroundTry for free, no card

Search company profiles

CONMED

Full company profile

uuid0002o5u

Namestring
CONMED
Legal namestring
CONMED Corporation
Websiteurl
conmed.com
Company typeenum
Public
Founded yearint
1970
Descriptiontext

CONMED Corporation is a global medical technology company founded in 1970 and publicly traded on NASDAQ under ticker CNMD, headquartered in Largo, Florida with manufacturing operations in Utica, New York; Westborough, Massachusetts; Cordova, Tennessee; and Chihuahua, Mexico. The company designs, manufactures, and distributes surgical devices, implants, and capital equipment across orthopedic and sports medicine, general/laparoscopic/robotic surgery, patient monitoring, and (until its 2026 exit) gastroenterology specialties, serving hospitals, ambulatory surgery centers, and physician offices in over 30 countries.

CONMED's core product platform spans proprietary insufflation (AirSeal iFS), electrosurgical generators (System 2450 and System 5000), smoke evacuation (PlumeSafe X5), surgical power tools (Hall Power, MicroFree), and a deep orthopedic and sports medicine portfolio including the BioBrace reinforced bioinductive implant, Y-Knot and Y-Knotless all-suture anchors, CartiMax viable cartilage allograft, NeoSpan nitinol compression implants, Infinity AIM meniscal repair, and Quantum total ankle system. The portfolio follows a platform-plus-modules architecture where capital equipment generates an installed base that drives high-margin recurring consumables, with approximately 86% of revenue coming from single-use products.

Revenue is generated primarily through a global direct sales force supplemented by regional distributors, with pricing negotiated through hospital, group purchasing organization, and integrated delivery network contracts. FY2025 revenue totaled approximately $1.37 billion with 5.2% constant currency growth, and management has guided to 4.5% to 6.0% organic constant currency growth in FY2026 with a $1.6 billion revenue target by 2028. The company is pursuing a portfolio rationalization strategy that included the 2022 acquisitions of In2Bones Global and Biorez, the 2025-2026 exit from the gastroenterology business, and the recent $150 million share repurchase program alongside a $450 million delayed draw term loan facility.

Short descriptiontext

CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical devices, implants, and capital equipment for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring, serving hospitals and ambulatory surgery centers in over 30 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLargo, United States
HQ citystring
Largo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices26 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical medical devices, minimally invasive surgery, orthopedic implants, electrosurgical equipment, surgical power tools
Industry3 codes
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Surgical Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Surgical Devices and Capital Equipment
TypeHardware Sales
Description

Sale of reusable surgical equipment including insufflation systems (AirSeal), electrosurgical generators, surgical imaging systems, and power tools. These represent higher-ticket capital purchases with longer replacement cycles.

conmed.com
2Single-Use Surgical Products (Consumables)
TypeHardware Sales
Description

Sale of single-use surgical devices and consumables including suture anchors, implants, instruments, smoke evacuation filters, and patient monitoring electrodes. Approximately 86% of revenue comes from single-use products.

finance.yahoo.com
3Implants
TypeHardware Sales
Description

Sale of orthopedic implants including suture anchors, interference screws, meniscal repair devices, and biologics like BioBrace and cartilage allografts for sports medicine and orthopedic procedures.

conmed.com
4Professional Services and Training
TypeProfessional Services
Description

Revenue from medical education programs, continuing education opportunities, and training services for healthcare professionals.

conmed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1BioBrace
Description

Reinforced bioinductive implant combining collagen with PLLA microfilaments for tendon healing

conmed.com
+4 more records
Core offering1 text field

CONMED Corporation designs, manufactures, and distributes surgical devices, capital equipment, and single-use implants for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring. Its portfolio spans capital systems such as AirSeal insufflation, electrosurgical generators, Hall surgical power tools, and surgical imaging, complemented by approximately 86% of revenue from single-use consumables including suture anchors, biologics (BioBrace, CartiMax), smoke evacuation filters, electrodes, and fixation devices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • AirSeal iFS positively affects patient intra and postoperative outcomes (clinical data backing)
+2 more records
Product overview1 text field

CONMED Corporation is a medical device company offering a comprehensive surgical equipment and consumables portfolio organized across multiple product categories: Orthopedics & Sports Medicine (implants, suture anchors, fixation devices, surgical power tools, biologics), General/Laparoscopic/Robotic Surgery (AirSeal insufflation systems, electrosurgical units, smoke evacuation, surgical instruments, imaging), Gastroenterology (biliary products, hemostasis clips, polypectomy devices), and Patient Monitoring (ECG/EEG electrodes, IV stabilization). The portfolio includes flagship products like the BioBrace reinforced bioinductive implant for soft tissue repair, AirSeal iFS intelligent insufflation system, Y-Knot suture anchors, CartiMax cartilage allograft, and the Hall Power surgical tool line with 55+ year heritage. The company operates a platform-plus-modules architecture with core technology systems (energy, insufflation, smoke evacuation) supplemented by procedure-specific consumables and implants.

Product and service2 records
1BioBrace Reinforced Bioinductive Implant
CategoryOrthopedic & Sports Medicine Implants
Description

Soft tissue augmentation implant combining highly porous Type I collagen with PLLA microfilaments for mechanical strength to support tendon healing and tissue growth; targets sports medicine and orthopedic surgeons.

2AirSeal iFS Intelligent Flow System
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-18
Description

Micro-Tech Endoscopy acquired global distribution rights for CONMED's Duraclip, Precisor, and Optibite product lines following CONMED's strategic decision to exit the gastroenterology market. This transaction enables CONMED to transition GI products to a specialized distributor while focusing on core surgical areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-02
Description

CONMED acquired Biorez for $85 million with potential earnout payments up to $165 million. Biorez developed the BioBrace implant technology, an FDA-cleared reinforced bioinductive implant for soft tissue repair that enhances CONMED's sports medicine portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-31
Description

CONMED announced plans to acquire In2Bones Global using proceeds from a $600 million convertible senior notes offering. In2Bones is a medical device company specializing in foot and ankle reconstruction products, strengthening CONMED's orthopedic portfolio.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

CONMED previously held exclusive US and Canadian distribution rights for Gore's VIABIL biliary stent. This distribution agreement was terminated as part of CONMED's strategic exit from the gastroenterology market effective January 1, 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Zimmer Biomet is one of the largest pure-play orthopedic medical device companies, with leadership in joint reconstruction, sports medicine, surgical, and biologics. It competes with CONMED in suture anchors, soft tissue repair, and extremity/foot & ankle reconstruction (overlapping with In2Bones and Quantum Total Ankle).

TypeBroad incumbent
Description

Johnson & Johnson's MedTech division (including Ethicon and DePuy Synthes) dominates surgical stapling, energy devices, sutures, and orthopedic reconstruction. It is a broad incumbent that competes with CONMED across nearly every product category in the OR and orthopedic settings.

TypeDirect peer
Description

Olympus is the global leader in endoscopy and minimally invasive surgical visualization. Its laparoscopic and arthroscopic imaging systems compete directly with CONMED's surgical imaging franchise, and it sells complementary energy and insufflation devices.

TypeDirect peer
Description

Stryker is a leading global medical device company with major franchises in orthopedic implants, sports medicine (arthroscopy), surgical instruments, and endoscopy. It is the most directly comparable peer to CONMED across general surgery, MIS, and orthopedic sports medicine, competing head-to-head on suture anchors, power tools, and visualization.

TypeBroad incumbent
Description

BD is a large medical technology company with a leading Medical and Procedural Solutions segment that includes surgical instruments, biosciences, and procedure solutions. It competes with CONMED in electrosurgical, patient monitoring electrodes, and surgical instruments.

TypeDirect peer
Description

Smith+Nephew is a UK-headquartered medical device company with strong franchises in orthopedic reconstruction, sports medicine (arthroscopic anchors, meniscal repair), and advanced wound management. Its sports medicine portfolio directly overlaps with CONMED's Y-Knot, Sequent, and BioBrace franchises.

TypeDirect peer
Description

Arthrex is a private, orthopedic-focused medical device company dominating sports medicine, arthroscopy, and soft tissue repair. Its suture anchor, biologic, and arthroscopic instrument portfolios are direct substitutes for CONMED's core orthopedic and sports medicine products.

TypeDirect peer
Description

Integra LifeSciences is a mid-cap specialty medical device company focused on neurosurgery, ENT, and orthopedics/tissue technologies. It is a direct peer in specialty orthopedic soft tissue repair and biologics, with comparable scale to CONMED.

TypeBroad incumbent
Description

Medtronic is a diversified medical technology leader with a large Surgical and Respiratory Interventions portfolio covering electrosurgical, insufflation, smoke evacuation, and stapling. It is a broad incumbent competitor to CONMED in the OR and laparoscopic surgery markets.

TypeBroad incumbent
Description

Boston Scientific is a large diversified medtech company with strong franchises in endoscopy, urology, and peripheral interventions. It overlaps with CONMED in urology and gynecology instruments and electrosurgical/energy devices through its legacy products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CONMED

Surgical Medical Devicesconmed.com

CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical devices, implants, and capital equipment for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring, serving hospitals and ambulatory surgery centers in over 30 countries.

What CONMED does

CONMED Corporation is a global medical technology company founded in 1970 and publicly traded on NASDAQ under ticker CNMD, headquartered in Largo, Florida with manufacturing operations in Utica, New York; Westborough, Massachusetts; Cordova, Tennessee; and Chihuahua, Mexico. The company designs, manufactures, and distributes surgical devices, implants, and capital equipment across orthopedic and sports medicine, general/laparoscopic/robotic surgery, patient monitoring, and (until its 2026 exit) gastroenterology specialties, serving hospitals, ambulatory surgery centers, and physician offices in over 30 countries.

CONMED's core product platform spans proprietary insufflation (AirSeal iFS), electrosurgical generators (System 2450 and System 5000), smoke evacuation (PlumeSafe X5), surgical power tools (Hall Power, MicroFree), and a deep orthopedic and sports medicine portfolio including the BioBrace reinforced bioinductive implant, Y-Knot and Y-Knotless all-suture anchors, CartiMax viable cartilage allograft, NeoSpan nitinol compression implants, Infinity AIM meniscal repair, and Quantum total ankle system. The portfolio follows a platform-plus-modules architecture where capital equipment generates an installed base that drives high-margin recurring consumables, with approximately 86% of revenue coming from single-use products.

Revenue is generated primarily through a global direct sales force supplemented by regional distributors, with pricing negotiated through hospital, group purchasing organization, and integrated delivery network contracts. FY2025 revenue totaled approximately $1.37 billion with 5.2% constant currency growth, and management has guided to 4.5% to 6.0% organic constant currency growth in FY2026 with a $1.6 billion revenue target by 2028. The company is pursuing a portfolio rationalization strategy that included the 2022 acquisitions of In2Bones Global and Biorez, the 2025-2026 exit from the gastroenterology business, and the recent $150 million share repurchase program alongside a $450 million delayed draw term loan facility.

CONMED firmographics

Firmographics
Name
CONMED
Legal name
CONMED Corporation
Website
https://conmed.com
Company type
Public
Founded year
1970
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical devices, implants, and capital equipment for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring, serving hospitals and ambulatory surgery centers in over 30 countries.
Ownership category
akta.pro rank

CONMED industry classification

Industry
Product category
Surgical Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Surgical medical devices
  • Minimally invasive surgery
  • Orthopedic implants
  • Electrosurgical equipment
  • Surgical power tools

Where CONMED is headquartered

Location

Headquarters

HQ city
Largo
HQ country
United States
HQ region
North America

Offices26 records

Markets served

CONMED business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Surgical Devices and Capital Equipment: Sale of reusable surgical equipment including insufflation systems (AirSeal), electrosurgical generators, surgical imaging systems, and power tools. These represent higher-ticket capital purchases with longer replacement cycles.
  2. Single-Use Surgical Products (Consumables): Sale of single-use surgical devices and consumables including suture anchors, implants, instruments, smoke evacuation filters, and patient monitoring electrodes. Approximately 86% of revenue comes from single-use products.
  3. Implants: Sale of orthopedic implants including suture anchors, interference screws, meniscal repair devices, and biologics like BioBrace and cartilage allografts for sports medicine and orthopedic procedures.
  4. Professional Services and Training: Revenue from medical education programs, continuing education opportunities, and training services for healthcare professionals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

CONMED product offering

Product offering

Core offering

CONMED Corporation designs, manufactures, and distributes surgical devices, capital equipment, and single-use implants for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring. Its portfolio spans capital systems such as AirSeal insufflation, electrosurgical generators, Hall surgical power tools, and surgical imaging, complemented by approximately 86% of revenue from single-use consumables including suture anchors, biologics (BioBrace, CartiMax), smoke evacuation filters, electrodes, and fixation devices.

Product overview

CONMED Corporation is a medical device company offering a comprehensive surgical equipment and consumables portfolio organized across multiple product categories: Orthopedics & Sports Medicine (implants, suture anchors, fixation devices, surgical power tools, biologics), General/Laparoscopic/Robotic Surgery (AirSeal insufflation systems, electrosurgical units, smoke evacuation, surgical instruments, imaging), Gastroenterology (biliary products, hemostasis clips, polypectomy devices), and Patient Monitoring (ECG/EEG electrodes, IV stabilization). The portfolio includes flagship products like the BioBrace reinforced bioinductive implant for soft tissue repair, AirSeal iFS intelligent insufflation system, Y-Knot suture anchors, CartiMax cartilage allograft, and the Hall Power surgical tool line with 55+ year heritage. The company operates a platform-plus-modules architecture with core technology systems (energy, insufflation, smoke evacuation) supplemented by procedure-specific consumables and implants.

Differentiator

Problem solved

Functional benefit

Brands

  • BioBrace: Reinforced bioinductive implant combining collagen with PLLA microfilaments for tendon healing
  • AirSeal
  • Hall Power
  • CartiMax
  • Y-Knot

Products and services

  • BioBrace Reinforced Bioinductive Implant Soft tissue augmentation implant combining highly porous Type I collagen with PLLA microfilaments for mechanical strength to support tendon healing and tissue growth; targets sports medicine and orthopedic surgeons.
  • AirSeal iFS Intelligent Flow System

Quantifiable outcome

  • AirSeal iFS positively affects patient intra and postoperative outcomes (clinical data backing)
  • +2 more outcomes

Companies that use CONMED

Customer profile

Segments5 records

Ideal customer profiles1 record

CONMED technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

CONMED partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Micro-Tech EndoscopyminorChannel Partner/ Reseller/ Distributor · 18 March 2026Micro-Tech Endoscopy acquired global distribution rights for CONMED's Duraclip, Precisor, and Optibite product lines following CONMED's strategic decision to exit the gastroenterology market. This transaction enables CONMED to transition GI products to a specialized distributor while focusing on core surgical areas.
  • BiorezcoreStrategic or Co-development Partner · 2 August 2022CONMED acquired Biorez for $85 million with potential earnout payments up to $165 million. Biorez developed the BioBrace implant technology, an FDA-cleared reinforced bioinductive implant for soft tissue repair that enhances CONMED's sports medicine portfolio.
  • In2Bones GlobalcoreStrategic or Co-development Partner · 31 May 2022CONMED announced plans to acquire In2Bones Global using proceeds from a $600 million convertible senior notes offering. In2Bones is a medical device company specializing in foot and ankle reconstruction products, strengthening CONMED's orthopedic portfolio.
  • W.L. Gore & AssociatesminorChannel Partner/ Reseller/ DistributorCONMED previously held exclusive US and Canadian distribution rights for Gore's VIABIL biliary stent. This distribution agreement was terminated as part of CONMED's strategic exit from the gastroenterology market effective January 1, 2026.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

CONMED competitors and assessment

Company assessment

Direct peers

  • Zimmer Biomet: Zimmer Biomet is one of the largest pure-play orthopedic medical device companies, with leadership in joint reconstruction, sports medicine, surgical, and biologics. It competes with CONMED in suture anchors, soft tissue repair, and extremity/foot & ankle reconstruction (overlapping with In2Bones and Quantum Total Ankle).
  • Olympus: Olympus is the global leader in endoscopy and minimally invasive surgical visualization. Its laparoscopic and arthroscopic imaging systems compete directly with CONMED's surgical imaging franchise, and it sells complementary energy and insufflation devices.
  • Stryker: Stryker is a leading global medical device company with major franchises in orthopedic implants, sports medicine (arthroscopy), surgical instruments, and endoscopy. It is the most directly comparable peer to CONMED across general surgery, MIS, and orthopedic sports medicine, competing head-to-head on suture anchors, power tools, and visualization.
  • Smith+Nephew: Smith+Nephew is a UK-headquartered medical device company with strong franchises in orthopedic reconstruction, sports medicine (arthroscopic anchors, meniscal repair), and advanced wound management. Its sports medicine portfolio directly overlaps with CONMED's Y-Knot, Sequent, and BioBrace franchises.
  • Arthrex: Arthrex is a private, orthopedic-focused medical device company dominating sports medicine, arthroscopy, and soft tissue repair. Its suture anchor, biologic, and arthroscopic instrument portfolios are direct substitutes for CONMED's core orthopedic and sports medicine products.
  • Integra LifeSciences: Integra LifeSciences is a mid-cap specialty medical device company focused on neurosurgery, ENT, and orthopedics/tissue technologies. It is a direct peer in specialty orthopedic soft tissue repair and biologics, with comparable scale to CONMED.

Broad incumbents

  • Johnson & Johnson MedTech: Johnson & Johnson's MedTech division (including Ethicon and DePuy Synthes) dominates surgical stapling, energy devices, sutures, and orthopedic reconstruction. It is a broad incumbent that competes with CONMED across nearly every product category in the OR and orthopedic settings.
  • Becton Dickinson (BD): BD is a large medical technology company with a leading Medical and Procedural Solutions segment that includes surgical instruments, biosciences, and procedure solutions. It competes with CONMED in electrosurgical, patient monitoring electrodes, and surgical instruments.
  • Medtronic: Medtronic is a diversified medical technology leader with a large Surgical and Respiratory Interventions portfolio covering electrosurgical, insufflation, smoke evacuation, and stapling. It is a broad incumbent competitor to CONMED in the OR and laparoscopic surgery markets.
  • Boston Scientific: Boston Scientific is a large diversified medtech company with strong franchises in endoscopy, urology, and peripheral interventions. It overlaps with CONMED in urology and gynecology instruments and electrosurgical/energy devices through its legacy products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

CONMED social profiles

Digital presence

CONMED compliance and trust

Trust signal

Compliance2 records

CONMED financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CONMED leadership team

Management profile

Number of profiles

Profiles15 records

CONMED subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

CONMED funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CONMED M&A and investment

M&A and investment

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CONMED

What does CONMED do?

CONMED Corporation designs, manufactures, and distributes surgical devices, capital equipment, and single-use implants for orthopedic, sports medicine, general/laparoscopic/robotic surgery, and patient monitoring. Its portfolio spans capital systems such as AirSeal insufflation, electrosurgical generators, Hall surgical power tools, and surgical imaging, complemented by approximately 86% of revenue from single-use consumables including suture anchors, biologics (BioBrace, CartiMax), smoke evacuation filters, electrodes, and fixation devices.

Is CONMED a public or private company?

CONMED is a public company. It is classified as public and is currently operating.

When was CONMED founded?

CONMED was founded in 1970. It employs 1,001 to 5,000 people.

Where is CONMED based?

CONMED is headquartered in Largo, United States, in the North America region.

How does CONMED make money?

Four revenue lines are on record. Surgical Devices and Capital Equipment is the primary driver. The others are single-Use Surgical Products (Consumables), implants and professional Services and Training.

Who are CONMED's main competitors?

Direct peers on record are Zimmer Biomet, Olympus, Stryker, Smith+Nephew, Arthrex and Integra LifeSciences. Broad incumbents are Johnson & Johnson MedTech, Becton Dickinson (BD), Medtronic and Boston Scientific.

Does CONMED have an API?

No public API is recorded for CONMED.

What industry is CONMED in?

CONMED's product category is Surgical Medical Devices. Its primary akta.pro industry code is HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.com+24%, +16%, +14%: our AI called these stocks and they surged in just two weeksInvesting.com's AI stock picks added on Nov. 1 have surged 14-24% in two weeks, with Bob's Discount Furniture up 23.9%, LivaNova 15.6%, and CONMED 14.2%. The companies reported Q3 revenue growth and raised full-year outlooks, while analyst price targets were increased.Simply Wall StCONMED (CNMD) Stock May Still Be A Bargain On EarningsCONMED's stock trades at a P/E of 20.5x, below the industry average of 25.3x, after a 63.1% drop over five years. The article suggests the current price may be a bargain relative to earnings power, but notes the next move depends on whether current earnings justify the share price.Investing.com+55% upside: These 3 undervalued AI-picked stocks just delivered standout earningsThree AI-picked stocks—Consensus Cloud Solutions, LivaNova, and BeOne Medicines—delivered strong Q3 earnings beats, with EPS surprises of +9.5%, +55.6%, and +18.8% respectively. The article also highlights CONMED Corporation's +55.1% fair value upside after a +4.0% EPS beat and buyout interest. It promotes InvestingPro's subscription at up to 55% off.Simply Wall StIs CONMED (CNMD) Fully Valued As Higher Q3 Earnings Meet Lower Sales Guidance?CONMED reported higher Q3 earnings but trimmed full-year sales guidance, pushing its share price to $51.50. Analysts value the stock at $45.50, citing a 13% overvaluation, while the P/E of 20.9x is below peers' 48.5x. The company is shifting focus to high-margin platforms like AirSeal and Buffalo Filter.Investing.com+21% MTD: This small-cap medtech is climbing on earnings and takeover speculationCONMED Corporation shares rose over 21% in November after Q3 adjusted EPS of $1.04 beat estimates and revenue grew 6.7% organically. The company raised full-year EPS guidance to $4.54–$4.61, and private equity buyout interest prompted price target hikes from JPMorgan and Wells Fargo.Business Wire BlogCONMED Corporation to Participate in the Jefferies Global Healthcare ConferenceCONMED Corporation announced its participation in the Jefferies Global Healthcare Conference, held November 16-19, 2026, in London. Management will host a fireside chat on Monday, November 16th at 11:30 a.m. GMT, with a live webcast and a 90-day replay available.Simply Wall StHas CONMED (CNMD) Fallen Far Enough to Justify Its Earnings?CONMED's share price has fallen 70.4% over the past five years, prompting a valuation review. The stock trades at a P/E of 18.0x, below the medical equipment industry average of 23.8x and peer group of 45.7x. Whether this undervaluation is justified depends on the durability of its margins and cash conversion.YahooThe top 5 analyst questions from CONMED’s Q3 earnings callCONMED reported Q3 revenue of $335.6 million, flat year-on-year, and adjusted EPS of $1.04, beating estimates. Management raised full-year adjusted EPS guidance to $4.58 and reconfirmed revenue guidance at $1.36 billion. Analysts asked about Q4 guidance, domestic orthopedic recovery, and BioBrace pricing.American Banking and Market NewsJPMorgan Chase & Co. Forecasts Strong Price Appreciation for CONMED (NYSE:CNMD) StockJPMorgan Chase raised its price target for CONMED from $45 to $50, keeping a neutral rating. The stock opened at $44.21, and CONMED reported Q3 adjusted EPS of $1.04, beating the $1.00 consensus, though revenue fell 0.7% year over year.MarketBeatCONMED (NYSE:CNMD) Announces FY 2026 Earnings GuidanceCONMED updated its FY2026 earnings guidance, projecting EPS of $4.540–$4.610 and revenue of $1.4 billion, both matching consensus estimates. The company's Q3 EPS of $1.04 beat estimates, while revenue fell 0.7% year-over-year. Analysts have an average "Reduce" rating with a $44.00 target price.